Evolus (EOLS) announced that its Chief Financial Officer, Sandra Beaver, has resigned effective June 13, 2025, to accept the same position at a private mental health and wellness technology company. Ms. Beaver’s resignation is not a result of any disagreement related to the company’s operations, policies or practices, including any accounting principles and practices, or related to any financial statements or disclosures.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EOLS:
- Evolus announces publication of U.S. pivotal study for Evolysse injectable gels
- Evolus, Inc. Reports Strong Q1 Growth Amid Challenges
- Evolus’s Strong Market Position and Growth Prospects Justify Buy Rating Despite Revenue Miss
- Evolus’s Growth Potential and Market Resilience: Analyst Recommends Buy Rating
- Evolus: Strong Growth Potential and Market Expansion Drive Buy Rating